Overview

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Status:
Completed

Trial end date:
2013-01-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with end-stage renal disease who recently started dialysis.

Phase:

Phase 2

Details

Lead Sponsor:

FibroGen

Collaborator:

Astellas Pharma Inc

Treatments:

Iron